Merit Medical names Sheri Lewis as global operations chief
Merit Medical Systems, Inc. announced the appointment of Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. Lewis brings 30 years of experience in global operations, manufacturing, and supply chain management. The current Chief Operating Officer, Neil Peterson, will transition to a Senior Advisor role before completing over 32 years of service with the company on March 5, 2027.
How Merit’s Leadership Transition in Global Operations at Merit Medical Systems (MMSI) Has Changed Its Investment Story
Merit Medical Systems (MMSI) recently appointed Sheri Lewis as Executive Vice President of Global Operations, bringing extensive experience to the role. This leadership change is expected to support operational execution and supply chain resilience, rather than immediately altering the investment narrative around key risks like tariffs or reimbursement. Investors will be watching how her expertise helps the company meet its raised 2026 revenue guidance while navigating ongoing challenges.
Merit Medical names Sheri Lewis as global operations chief By Investing.com
Merit Medical Systems, Inc. announced the appointment of Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. Lewis brings 30 years of experience from various leadership roles in global operations, manufacturing, and supply chain management at companies like SkinHealth Systems, Avantor, Medtronic, and Honeywell. She will succeed current Chief Operating Officer Neil Peterson, who will transition to a Senior Advisor role until March 5, 2027, concluding over 32 years of service with the company.
Merit Medical names Sheri Lewis as global operations chief By Investing.com
Merit Medical Systems, Inc. (NASDAQ:MMSI) has appointed Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. Lewis brings 30 years of experience from previous senior roles at companies like Medtronic and Honeywell. This appointment follows current COO Neil Peterson's transition to a Senior Advisor role before his retirement in March 2027.
Merit Medical Announces Global Operations Leadership Transition
Merit Medical Systems, Inc. announced that Sheri Lewis will join as Executive Vice President of Global Operations, effective August 31, 2026. Ms. Lewis brings three decades of experience in global operations, manufacturing, and supply chain management from various senior roles. Neil Peterson, the current Chief Operating Officer, will transition to a Senior Advisor role to ensure a smooth handover and will complete his 32 years of service to Merit in March 2027.
After more than 32 years, Merit Medical's chief operating officer will become a senior adviser
Merit Medical Systems (NASDAQ: MMSI) has announced a leadership transition in its global operations. Sheri Lewis will join as Executive Vice President of Global Operations, bringing 30 years of experience, while current COO Neil Peterson will transition to Senior Advisor before concluding his 32-year tenure with the company. This move aims to support continuity and strategic growth.
Merit Medical Announces Global Operations Leadership Transition
Merit Medical Systems, Inc. announced that Sheri Lewis will join the company as Executive Vice President of Global Operations, effective August 31, 2026. Ms. Lewis brings extensive experience from previous senior roles in global operations, manufacturing, and supply chain management. Neil Peterson, current Chief Operating Officer, will transition to a Senior Advisor role to ensure a smooth handover before completing his 32-year tenure with Merit Medical on March 5, 2027.
Merit Medical Systems Eyes New Long-Range Plan as Growth, Margins Gain Momentum
Merit Medical Systems (MMSI) is developing a new long-range plan under its new CEO, Martha, focusing on a reorganized reporting structure with Foundational and Therapeutic product categories. The company is seeing strong momentum in revenue growth and margin expansion, with a focus on strategic acquisitions that deepen existing platforms. Merit's CFO, Raul Parra, indicated that the new plan will likely be announced with Q4 earnings and will continue to prioritize revenue growth, operating margin expansion, and free cash flow while seeking further margin improvements.
Merit Medical Systems Eyes New Long-Range Plan as Growth, Margins Gain Momentum
Merit Medical Systems (MMSI) is developing a new long-range plan, building on recent revenue and margin growth under new CEO Martha. The company has reorganized its reporting structure into Foundational and Therapeutic product categories and is focusing on disciplined M&A to deepen existing market positions. Merit sees continued opportunities for margin improvement, though not at the same rapid pace as in recent years, and remains optimistic about its business despite normal seasonality.
Merit Medical Systems, Inc. $MMSI Shares Purchased by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in Merit Medical Systems (MMSI) by 200.3% in the first quarter, now owning 17,612 shares valued at approximately $1.21 million. This comes as institutional investors collectively hold 99.66% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $100. Merit Medical also exceeded its recent quarterly earnings expectations, reporting $1.19 EPS against a $0.96 consensus and revenues of $418.84 million, a 9.5% increase year-over-year.
Merit Medical Systems, Inc. $MMSI Shares Sold by Bank of America Corp DE
Bank of America Corp DE reduced its stake in Merit Medical Systems (NASDAQ:MMSI) by 20.8% in the first quarter, selling 152,248 shares and retaining 580,918 shares valued at approximately $40 million. Institutional investors hold 99.66% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $100. Merit Medical exceeded quarterly earnings expectations, reporting $1.19 EPS against an estimated $0.96, and revenue of $418.84 million, a 9.5% increase year-over-year.
Merit Medical Systems, Inc. (MMSI) Stock Forecasts
Argus has raised its target price for Merit Medical Systems Inc. (MMSI) to $100.00, citing the company's role as a medical equipment developer and manufacturer. The report, published on August 12, 2026, highlights MMSI's products for interventional cardiology, radiology, and endoscopy procedures. Full access to the report is available through Yahoo Finance Silver.
Bank of America Forecasts Strong Price Appreciation for Merit Medical Systems (NASDAQ:MMSI) Stock
Bank of America has raised its price target for Merit Medical Systems (NASDAQ:MMSI) to $97 from $92, while maintaining a "neutral" rating, indicating a potential 6.36% upside. The company recently surpassed quarterly earnings expectations, reporting $1.19 EPS against a $0.96 consensus and revenue of $418.84 million, a 9.5% increase year-over-year. Institutional investors hold 99.66% of MMSI shares, and the stock has a "Moderate Buy" consensus rating from analysts with an average target price of $100.
MMSI Maintained by B of A Securities -- Price Target Raised to $97.00
B of A Securities maintained a neutral rating on Merit Medical Systems (MMSI) but raised its price target from $92.00 to $97.00. GuruFocus indicates MMSI is undervalued by 4.9% with a strong GF Score of 86/100, excelling in growth and valuation. While gurus show positive sentiment, insider sales suggest caution, presenting a mixed outlook for investors.
Merit Medical at Bank of America smid cap virtual conference: growth, margins
Merit Medical Systems (MMSI) recently participated in the Bank of America SMID Cap Virtual Conference, where CFO Raul Parra highlighted the company's transition towards stronger growth, wider margins, and a streamlined reporting structure. The company raised its 2024 organic constant-currency revenue growth outlook and discussed significant operating margin expansion since 2019. Merit Medical also outlined its strategic focus on existing end markets, tuck-in acquisitions, and the upcoming long-range plan, while addressing leadership changes and the active M&A landscape.
14-Day Rally Sends Merit Medical Systems Stock Up 25%
The article "14-Day Rally Sends Merit Medical Systems Stock Up 25%" indicates a significant recent increase in the stock value of Merit Medical Systems. However, the provided content is largely boilerplate and does not contain the actual article details regarding this rally. It primarily consists of navigation links, copyright information, and disclaimers about financial data and interactive models.
Merit Medical Systems Stock Climbs 25% On A 14-Day Winning Streak
Merit Medical Systems (MMSI) stock has experienced a significant surge, climbing 25% over a 14-day winning streak, adding $1.1 billion to its market value. While this momentum is notable, the article advises investors to look beyond the streak and evaluate fundamental support, noting the company's above-median revenue growth but below-median operating margin and higher price-to-earnings multiple compared to the S&P 500 median. It emphasizes that streaks eventually end and encourages a disciplined approach to investment decisions based on thorough analysis rather than just market momentum.
Merit Medical Systems (MMSI) Is Up 6.2% After Raising 2026 Outlook And Q2 Beat Expectations – Has The Bull Case Changed?
Merit Medical Systems (MMSI) saw its stock rise by 6.2% after reporting strong second-quarter 2026 results, including higher sales and net income, and subsequently raising its full-year 2026 revenue outlook. While the upgraded guidance supports stronger near-term earnings, the company still faces risks such as product recalls and reimbursement issues. The article explores how these developments impact Merit's investment narrative and fair value.
BofA raises Merit Medical stock price target on growth outlook
BofA Securities has increased its price target for Merit Medical Systems (NASDAQ:MMSI) to $97 from $92, while maintaining a Neutral rating, citing confidence in the company's growth and margin outlook for 2026 and beyond. The firm's decision is based on an increased 2027 earnings per share estimate and higher peer multiples. This adjustment follows Merit Medical's strong Q2 performance, which also led Canaccord and Needham to raise their price targets.
Assenagon Asset Management S.A. Sells 70,521 Shares of Merit Medical Systems, Inc. $MMSI
Assenagon Asset Management S.A. significantly reduced its stake in Merit Medical Systems (NASDAQ:MMSI) by selling 70,521 shares, lowering its holdings by 34.2%. Despite this reduction, institutional investors collectively own 99.66% of the company, which recently reported strong quarterly earnings exceeding expectations and issued positive fiscal 2026 EPS guidance. Analysts maintain a "Moderate Buy" rating with an average price target above the current stock price.
Merit Medical Systems Stock Climbs 25% On A 13-Day Winning Streak
Merit Medical Systems (MMSI) stock has surged 25% over 13 consecutive trading days, adding $1.1 billion to its market value and bringing its total valuation to $5.4 billion. This impressive streak significantly outperforms the S&P 500's 4.3% gain over the same period, suggesting company-specific momentum driven by revenue growth of 10.2% over the last twelve months. Investors are prompted to re-evaluate the company's fundamentals, including its P/E multiple of 37.4, to determine if the current price is justified.
Why Merit Medical Systems (MMSI) Is Up 14.4% After Raising 2026 Revenue Outlook And Margins
Merit Medical Systems (MMSI) saw its stock rise by 14.4% after reporting strong Q2 2026 results and raising its full-year 2026 revenue outlook to US$1.631 billion–US$1.643 billion. This positive revision is attributed to better-than-expected first-half performance, recent acquisitions, and efficiency gains. While the raised guidance supports the company's near-term growth and profitability, investors are still weighing potential risks like WRAPSODY reimbursement delays and ongoing tariff pressures.
Merit Medical Systems (NASDAQ:MMSI) Earns "Buy" Rating from BTIG Research
BTIG Research has reaffirmed its "Buy" rating for Merit Medical Systems (NASDAQ:MMSI), setting a price target of $105, which suggests a 17% upside. The company recently surpassed earnings estimates with an EPS of $1.19 and saw its revenue increase by 9.5% year-over-year to $418.84 million. Merit Medical Systems currently holds a "Moderate Buy" consensus rating from analysts, with institutional investors owning nearly all of its stock.
Gradient Investments LLC Buys Shares of 23,890 Merit Medical Systems, Inc. $MMSI
Gradient Investments LLC has acquired 23,890 shares of Merit Medical Systems, Inc. (NASDAQ:MMSI), valued at approximately $1.66 million, contributing to the significant institutional ownership of 99.66% in the company. Merit Medical Systems recently reported strong quarterly earnings, beating analyst estimates with an EPS of $1.19 and a 9.5% revenue increase, and provided optimistic fiscal 2026 EPS guidance. Analysts maintain a "Moderate Buy" consensus rating for MMSI, with an average price target of $100.30, suggesting potential upside from its current share price.
First Trust Advisors LP Has $2.48 Million Position in Merit Medical Systems, Inc. $MMSI
First Trust Advisors LP significantly increased its stake in Merit Medical Systems, Inc. (MMSI) by 479.1% in the first quarter, now holding 35,907 shares valued at $2.48 million. Institutional investors collectively own 99.66% of MMSI, and analysts have a "Moderate Buy" consensus with an average price target of $100.30. Merit Medical reported strong quarterly earnings of $1.19 EPS, beating estimates, and revenue grew 9.5% year-over-year.
Merit Medical Systems, Inc. (NASDAQ:MMSI) Given Average Recommendation of "Moderate Buy" by Brokerages
Merit Medical Systems, Inc. (NASDAQ:MMSI) has received a consensus "Moderate Buy" rating from brokerages, with eight out of eleven analysts recommending a buy and three suggesting a hold. The average 12-month price target is $100.30, exceeding its opening price of $89.04. The company recently surpassed quarterly earnings and revenue expectations, reporting $1.19 EPS against an estimated $0.96, and revenue of $418.84 million against an estimated $405.25 million, representing a 9.5% year-over-year increase.
Merit Medical Systems Chief Operating Officer Neil Peterson Sells 68% Of Holding
Merit Medical Systems' Chief Operating Officer, Neil Peterson, recently sold 68% of his holdings, netting US$1.8m. This significant sale, along with other insider selling activities totaling US$7.3m over the last year, raises some concerns despite the company's profitability and strong insider ownership. While high insider ownership is positive, the consistent selling suggests caution.
Merit Medical Systems (MMSI) COO Neil Peterson Sells 21,449 Shares
Merit Medical Systems (MMSI) COO Neil Peterson sold 21,449 shares of the company for approximately $1.82 million, reducing his direct ownership to 25,551 shares. This sale is part of a broader insider selling trend, with 9 insider sells versus 5 buys over the past year. Despite this, the company is considered "Fairly Valued" by GuruFocus with a GF Value of $95.76, and all 6 tracked institutional gurus have increased their holdings, suggesting a divergence in sentiment between insiders and institutional investors.
Merit Medical to Participate in Upcoming Investors Conferences in August
Merit Medical Systems, Inc. announced its participation in two investor conferences in August 2026. Management will hold fireside chats at the Canaccord Genuity 46th Annual Growth Conference and the Bank of America SMID Cap Conference. Live audio webcasts and replays will be available on the company's investor relations website.
Merit Medical Systems Inc (MMSI) COO sells 21,449 shares at $85
Merit Medical Systems Inc. COO Neil W. Peterson sold 21,449 shares of common stock at $85.00 per share on August 4, 2026. Following this transaction, Peterson directly holds 25,551 common shares and non-qualified stock options for an additional 38,576 shares at various exercise prices and vesting schedules. The sale generated $1.82 million and was reported via a Form 4 filing.
Two Merit Medical fireside chats will stream live Aug. 11-12
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced its participation in two investor conferences in August 2026. Management will host a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11 and at the Bank of America SMID Cap Conference on August 12. Live audio webcasts and 90-day replays will be available on the company's investor relations website.
Proposed MMSI (MMSI) insider stock sale disclosed in Form 144 filing
A Form 144 filing indicates a proposed sale of up to 21,449 shares of Merit Medical Systems Inc. (MMSI) common stock by an affiliate. The shares, consisting of Performance Shares and Restricted Stock granted in 2025 and 2026, are expected to be sold on the NASDAQ on or after August 4, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services. This notice provides advance disclosure of potential market sales.
MERIT MEDICAL SYSTEMS INC : NEEDHAM RAISES TARGET PRICE TO $101 FROM $90
Needham has increased its target price for Merit Medical Systems Inc (MMSI.O) from $90 to $101. This update reflects a positive revision in the analyst's outlook for the company. The news was reported by Reuters.
Merit Medical Systems, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:MMSI) 2026-07-31
Merit Medical Systems, Inc. (MMSI) released its Q2 2026 earnings call presentation, reporting an EPS of $1.19, which beat estimates by $0.23. The company also reported revenues of $418.84 million, a 9.51% year-over-year increase, beating estimates by $13.50 million. This slide deck accompanies their Q2 earnings call.
Merit Medical Systems, Inc. Stock 12‑Month Price Target Raised to $99.82, Implies 20% Upside
Merit Medical Systems, Inc.'s average 12-month price target has been increased to $99.82 from $90.09, based on estimates from 11 analysts. This updated target suggests a potential upside of approximately 20% from the July 30 closing price. The consensus rating for MMSI stock remains a "Buy," with 9 out of 11 analysts recommending a Buy and 2 recommending a Hold.
MERIT MEDICAL SYSTEMS, INC. : WELLS FARGO RAISES TARGET PRICE TO $83 FROM $74
Wells Fargo has increased its target price for MERIT MEDICAL SYSTEMS, INC. (MMSI.O) to $83 from $74. This update was reported by Reuters on July 31, 2026. The article states that the content reflects the author's opinion and is not investment advice.
Merit Medical Systems Q2 Non-GAAP Earnings, Net Sales Rise; Lifts 2026 Guidance
Merit Medical Systems reported increased non-GAAP earnings and net sales for Q2, leading the company to raise its financial guidance for 2026. This positive performance indicates strong operational results and an optimistic outlook for the coming year.
Merit Medical: Q2 Earnings Snapshot
This article provides a brief snapshot of Merit Medical's Q2 earnings. Due to the lack of detailed financial information, specific figures or performance metrics cannot be reported in the summary.
Merit Medical Systems, Inc. Stock 12‑Month Price Target Raised to $98.36, Implies 18% Upside
Analysts have raised the average 12-month price target for Merit Medical Systems, Inc. (MMSI) stock to $99.82 from $90.09, implying a 20% upside based on the Jul. 30 closing price. The consensus rating from 11 analysts remains "Buy," with 9 Buys, 2 Holds, and 0 Sells. This update reflects a positive outlook on the company's stock performance.
Canaccord raises Merit Medical stock price target on strong Q2 results
Canaccord increased its price target for Merit Medical Systems (NASDAQ:MMSI) to $94 from $85, maintaining a Buy rating after the company reported strong second-quarter results. Merit Medical surpassed revenue and EPS estimates, showing 10% year-over-year revenue growth and its strongest organic growth in three years, leading to raised full-year guidance. The firm believes Merit Medical's conservative guidance and execution on margin expansion, along with strategic acquisitions, could offer further upside for investors.
MERIT MEDICAL SYSTEMS INC : NEEDHAM RAISES TARGET PRICE TO $101 FROM $90
Needham has increased its target price for Merit Medical Systems Inc. (MMSI.O) shares to $101 from the previous $90. This adjustment indicates a more optimistic outlook on the company's future stock performance by the analyst firm.
Merit Medical Systems, Inc. Stock 12‑Month Price Target Raised to $97.36, Implies 17% Upside
The average 12-month price target for Merit Medical Systems, Inc. (MMSI) stock has been raised to $97.36 from $90.09, based on estimates from 11 analysts. This new target implies a potential upside of approximately 17% from the July 30 closing price. The consensus analyst rating remains a "Buy," with 9 out of 11 analysts recommending a Buy and 2 recommending a Hold.
Earnings call transcript: Merit Medical tops Q2 2026 estimates and lifts outlook
Merit Medical Systems reported strong Q2 2026 results, exceeding Wall Street expectations for profit and sales with adjusted earnings of $1.19 per share and revenue of $418.8 million. The company also raised its full-year outlook, citing its strongest organic growth in three years and broad-based performance across its product groups. Key drivers included robust growth in foundational and therapeutic products, improved OEM business, and successful integration of recent acquisitions, despite anticipating seasonal softness in Q3.
Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance
Merit Medical Systems, Inc. announced strong financial results for the second quarter of 2026, surpassing expectations with a 9% organic, constant currency revenue growth. The company reported a 10% increase in U.S. sales and improved non-GAAP operating margin and EPS. Reflecting these robust results, Merit Medical has raised its full-year 2026 revenue and non-GAAP earnings per share guidance, confident in its continued growth initiatives and strategic long-term planning.
Merit Medical posts Q2 beat, raises FY26 EPS and sales guidance
Merit Medical Systems exceeded its Q2 2026 expectations with $418.8 million in revenue, a 10% increase year-over-year, and non-GAAP EPS of $1.19, up 18%. This strong performance, driven by robust U.S. demand and margin expansion, led the company to raise its full-year 2026 adjusted EPS guidance to $4.25-$4.35 and total revenue guidance to $1.631 billion-$1.643 billion. The company also reported significant margin expansion and healthy cash flow from operations.
Merit Medical Systems (NASDAQ:MMSI) Jumps After Q2 Earnings Beat and Revenue Slightly Ahead of Estimates
Merit Medical Systems (NASDAQ:MMSI) reported strong second-quarter 2026 results, with non-GAAP EPS of $1.19 significantly beating analyst estimates of $0.9782 and revenue of $418.8 million slightly exceeding projections. This performance, driven by strength in cardiovascular and endoscopy segments, led to a positive market reaction with shares rising 4.9% after hours and contributing to recent stock momentum. The company also updated its full-year guidance, indicating optimism for continued growth.
(MMSI) Merit Medical Systems Now Expects Full Year 2026 Adjusted EPS Range $4.25 - $4.35, vs. FactSet Est of $4.07
Merit Medical Systems (MMSI) has updated its guidance for the full year 2026, now expecting adjusted EPS to be in the range of $4.25 - $4.35. This revised forecast is notably higher than the FactSet estimate of $4.07. The company had also previously announced a higher expected revenue range for the same period.
Merit Medical Systems (NASDAQ: MMSI) Q2 earnings rise on margin gains
Merit Medical Systems reported a strong Q2 2026, with net sales increasing by 9.5% to $418.8 million and net income rising to $38.8 million, or $0.65 diluted EPS, driven by improved gross profit margins. The company's foundational and therapeutic product categories both saw significant growth, notably in cardiac therapies and endoscopy, and it completed the acquisition of View Point Medical. Merit also noted receiving $6.9 million in refunds from previously paid IEEPA tariffs, contributing to the improved profitability.
Merit Medical reports $418.8M revenue and 9% organic growth
Merit Medical (NASDAQ: MMSI) reported strong second-quarter 2026 financial results, with revenue up 10% to $418.8 million and organic growth of 9%. The company also raised its full-year 2026 revenue guidance to $1.631–$1.643 billion and non-GAAP EPS guidance to $4.25–$4.35, reflecting confidence in continued growth and profitability despite a decrease in year-to-date operating and free cash flow.
Earnings To Watch: Merit Medical Systems (MMSI) Reports Q2 Results Tomorrow
Merit Medical Systems (MMSI) is set to announce its Q2 earnings results after the bell tomorrow. The market anticipates a 6% year-on-year revenue growth. The company has a history of exceeding Wall Street's expectations and has seen positive investor sentiment in the healthcare equipment and supplies segment.
